Email this article DEVELOPMENT OF A MULTIPLEX ALLELE-SPECIFIC REAL-TIME PCR METHOD FOR DETECTION OF PIK3CA GENE SOMATIC MUTATIONS AND ITS VALIDATION IN THE TUMORS OF BREAST CANCER PATIENTS
- Authors: Filipenko M.L.1, Shamovskaya D.V.1, Oskina N.A.1, Oscorbin I.P.1,2, Khrapov E.A.1, Ovchinnikova L.K.3, Gershteyn E.S.3, Kushlinskii N.E.3
-
Affiliations:
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Sciences, Novosibirsk
- Novosibirsk State University
- N.N. Blokhin Russian Cancer Research Cente, Moscow
- Issue: No 41 (2015)
- Pages: 12-18
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/70
- DOI: https://doi.org/10.18786/2072-0505-2015-41-12-18
- ID: 70
Cite item
Full Text
Abstract
Aim: To develop a highly sensitive real-time polymerase chain reaction (PCR) system for detection of somatic mutations in 542 and 545 codons of exon 9 and 1047 codon of exon 20 of PIK3CA gene comprising more than 80% of all somatic mutations in this gene for application on histological material without macroand microdissection, and to analyze associations between these mutations and clinical and pathological characteristics of breast tumors.
Materials and methods: The Allele-specific real-time PCR method with signal detection by TaqMan probes was used. For determination of its analytical sensitivity, plasmids carrying the mutations studied were constructed by standard genetic engineering methods using mutagenesis. DNA samples carrying various mutated/wild type DNA ratios (5.0; 2.0; 1.0; 0.5, 0.25%) were prepared. Results: Multiplex allele-specific real-time PCR method for detection of most common mutations in PIK3CA gene: p.E542K c.1624G>A, p.E545K c.1633G>A, p.H1047R c.3140A>G, p.H1047L c.3140A>T – was developed and optimized.
Analytical sensitivity of mutation detection comprised 0.5% for p.E542K and 0.25% for p.E545K, p.H1047R and H1047L enzyme.
Conclusion: The method developed for detection of somatic mutations in PIK3CA gene is sufficiently sensitive, specific and efficient, that allows to propose it for a routine screening in clinical diagnostic laboratories for evaluation of disease prognosis and monitoring of response to therapy and its modification.
About the authors
M. L. Filipenko
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Sciences, Novosibirsk
Author for correspondence.
Email: mlfilipenko@gmail.com
Filipenko Maksim Leonidovich – PhD (Biol.), Head of Laboratory of Pharmacogenomics, Research Fellow Russian Federation
D. V. Shamovskaya
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Sciences, Novosibirsk
Email: mlfilipenko@gmail.com
Shamovskaya Dar'ya Vadimovna – Research Fellow Russian Federation
N. A. Oskina
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Sciences, Novosibirsk
Email: mlfilipenko@gmail.com
Oskina Natal'ya Aleksandrovna – Research Fellow Russian Federation
I. P. Oscorbin
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Sciences, Novosibirsk; Novosibirsk State University
Email: mlfilipenko@gmail.com
Oscorbin Igor Petrovich – Research Fellow, PhD student Russian Federation
E. A. Khrapov
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Sciences, Novosibirsk
Email: mlfilipenko@gmail.com
Khrapov Evgeniy Aleksandrovich – Research Fellow; Novosibirsk State University Russian Federation
L. K. Ovchinnikova
N.N. Blokhin Russian Cancer Research Cente, Moscow
Email: mlfilipenko@gmail.com
Ovchinnikova Larisa Konstantinovna – PhD, Surgeon-Oncologist, Department of Mammary Gland Tumors Russian Federation
E. S. Gershteyn
N.N. Blokhin Russian Cancer Research Cente, Moscow
Email: mlfilipenko@gmail.com
Gershteyn Elena Sergeevna – Doctor of Biol. Sci., Professor, Leading Research Fellow, Clinical Biochemistry Laboratory Russian Federation
N. E. Kushlinskii
N.N. Blokhin Russian Cancer Research Cente, Moscow
Email: mlfilipenko@gmail.com
Kushlinskii Nikolay Evgen'evich – MD, PhD, Professor, Member-Correspondent of Russian Academy of Sciences, Head of Clinical Biochemistry Laboratory Russian Federation
References
- Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.
- Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006;94(4):455–9.
- COSMIC database http://cancer.sanger.ac.uk/cosmic
- Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene. 2008;27(41):5486– 96. doi: 10.1038/onc.2008.244.
- Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A. 2009;106(8):2835–40. doi: 10.1073/ pnas.0813351106.
- Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17(7):2503–16.
- Board RE, Thelwell NJ, Ravetto PF, Little S, Ranson M, Dive C, Hughes A, Whitcombe D. Multiplexed assays for detection of mutations in PIK3CA. Clin Chem. 2008;54(4):757–60. doi: 10.1373/clinchem.2007.098376.
- Li B, Kadura I, Fu DJ, Watson DE. Genotyping with TaqMAMA. Genomics. 2004;83(2):311–20.
- Pang H, Flinn R, Patsialou A, Wyckoff J, Roussos ET, Wu H, Pozzuto M, Goswami S, Condeelis JS, Bresnick AR, Segall JE, Backer JM. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res. 2009;69(23):8868–76. doi: 10.1158/0008-5472.CAN-09-1968.
- Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 2007;317(5835):239–42.
- Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene. 2010;29(37):5193–203. doi: 10.1038/onc.2010.257.
Supplementary files
